Pharmacoeconomic review report : Ivabradine hydrochloride (Lancora)

Pharmacoeconomic review report Ivabradine hydrochloride (Lancora)

Ivabradine (Lancora) is a heart-rate regulating drug for the management of heart failure (HF) that acts by selectively inhibiting the If current in the sinus node. Ivabradine is indicated for the treatment of stable chronic HF with reduced left ventricular ejection fraction (LVEF) d 35% in adult pat...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2017.
Materias:
Drugs > Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269506719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Information on the Pharmacoeconomic Submission
  • 1. Summary of the Manufacturer's Pharmacoeconomic Submission
  • 2. Manufacturer's Base Case
  • 3. Summary of Manufacturer's Sensitivity Analyses
  • 4. Limitations of Manufacturer's Submission
  • 5. CADTH Common Drug Review Reanalyses
  • 6. Issues for Consideration
  • 7. Patient Input
  • 8. Conclusions
  • APPENDIX 1. Cost Comparison
  • APPENDIX 2. Summary of Key Outcomes
  • APPENDIX 3. Additional Information
  • APPENDIX 4. Summary of Other HTA Reviews of Ivabradine
  • APPENDIX 5. Reviewer Worksheets
  • References.

Ejemplares similares